Skip Navigation



Rheumatology Advance Access published online on March 7, 2008
Rheumatology, doi:10.1093/rheumatology/ken104
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/5/735    most recent
ken104v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sfikakis, P. P.
Right arrow Articles by Black, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sfikakis, P. P.
Right arrow Articles by Black, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Imatinib for the treatment of refractory, diffuse systemic sclerosis

P. P. Sfikakis1, V. G. Gorgoulis2, C. G. Katsiari1, K. Evangelou2, C. Kostopoulos3 and C. M. Black4

1First Department of Propedeutic and Internal Medicine, Laikon Hospital, 2Histology-Embryology Department, 3Pulmonary Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School, Athens, Greece and 4Royal Free Hospital, University College London, London, UK

Correspondence to: P. P. Sfikakis, 18, Ipsilantou Str, 10676, Athens, Greece. E-mail: psfikakis@med.uoa.gr

The first 10% of the full text of this article appears below.

SIR, We report on the beneficial, 6-month compassionate use of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) in a 24-yr-old woman with severe diffuse systemic sclerosis of 7 yrs duration. The patient presented in 1999 with Raynaud's phenomenon, followed shortly after by widespread diffuse scleroderma. A year later she was seen at the Royal Free Hospital, having a modified Rodnan skin score of 39 (maximum 51), muscle weakness, flexed hands and evidence of early interstitial lung fibrosis. She received 6-monthly intravenous (IV) pulses of cyclophosphamide, resulting in a decrease of skin score to 30. Subsequently, she . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. H. W. Distler and O. Distler
Imatinib as a novel therapeutic approach for fibrotic disorders
Rheumatology, January 1, 2009; 48(1): 2 - 4.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, and V. Rivera
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide
Rheumatology, January 1, 2009; 48(1): 49 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Juarez, R. Marshall, C. Denton, and R. Evely
Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine
Rheumatology, November 1, 2008; 47(11): 1734 - 1735.
[Full Text] [PDF]